New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases

A method for the treatment of bronchiectasis, said method comprising administering to a patient a Compound (I):

• wherein Compound (I) is administered in a daily dose of 1.5 to 5 mg.

A method for the treatment of bronchiectasis, said method comprising administering to a patient a crystalline form of a Compound (I):

• wherein compound (I) is administered in a daily dose of 1.5 to 5 mg.

A method for the treatment of bronchiectasis, said method comprising administering to a patient a pharmaceutical composition comprising the Compound of formula (I):

• and at least one pharmaceutically acceptable carrier or diluent,
• wherein Compound (I) is administered in a once daily dose of 2.5 mg.

A method for the treatment of bronchiectasis, said method comprising administering to a patient an oral pharmaceutical composition consisting essentially of 1 mg, 2.5 mg, or 5 mg of Compound (I):

• and optionally of one or more pharmaceutically acceptable carriers or excipients, wherein this oral pharmaceutical composition is administered to the patient once daily.

A method for the treatment or prevention of ANCA-associated vasculitis, said method comprising administering to a patient a Compound (I):

• wherein compound (I) is administered in a daily dose of 1.5 to 5 mg.

A method for the treatment or prevention of ANCA-associated vasculitis, said method comprising administering to a patient a pharmaceutical composition comprising the Compound of formula (I):

• and at least one pharmaceutically acceptable carrier or diluent,
• wherein Compound (I) is administered in a once daily dose of 2.5 mg.

A method for the treatment of ANCA-associated vasculitis, said method comprising administering to a patient an oral pharmaceutical composition consisting essentially of 1 mg, 2.5 mg, or 5 mg of Compound (I):

• and optionally of one or more pharmaceutically acceptable carriers or excipients, wherein this oral pharmaceutical composition is administered to the patient once daily.

A method for the treatment of ANCA-associated vasculitis, said method comprising administering to a patient a Compound (I):

• wherein Compound (I) is administered in a daily dose of 2.5 or 5 mg.